BCR-Abl-targeting TKIs inhibit the activity of the BCR-Abl fusion protein, which is characteristic of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [63]. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.